Prasad指出，新药与标准化疗联用时无法判断新药的贡献，医生凭个人印象下结论并不可靠。
如果你把新药与久经验证的基础方案（新药+化疗）联用，就不可能知道新药到底增加了什么。如果有医生说“我从没见过单用化疗有这么好的反应，所以新药一定有帮助”，那这位医生需要更多教育，或者根据你的目标把他招募为KOL。原文 (en)
If you use your novel drug with a tried and true backbone— new drug + chemo— it is impossible to know what <new drug> adds. If you have a doctor who says “I’ve never seen responses this good with chemo alone, ergo new drug must have helped” That doctor needs more education — or should be recruited as your kol depending on your goal.
Prasad 认为 AI 工具和私营市场而非政府最能解决获得医疗咨询的难题，其信息质量超过大多数医生。
解决方案很可能来自私营市场和 AI 驱动。这些工具大幅降低了提出医疗问题的门槛，其信息质量超过大多数医生。技术而非政府最适合解决这一问题。原文 (en)
The solution here is likely to be private markets and AI driven. These tools dramatically lower the barrier to ask medical questions, and the quality of the information surpasses most doctors. Technology and not government is best poised to address this.
Prasad 称许多新药和器械无效或弊大于利，ACA 让游说者把未经证实的产品纳入公共支出，使问题恶化。
许多新上市的药物、器械和疗法无效，或危害大于获益。ACA 允许游说者把越来越多未经证实的疗法、策略和产品加到公共账单上，只会加剧这一问题。原文 (en)
Many novel drugs, devices and procedures debuted don’t work/ have harms exceeding benefits. The ACA has only exacerbated this problem by allowing lobbyists to add more and more unproven remedies, tactics, strategies and products to the public tab.
Prasad 怀疑政府控费会以价值为导向，预计会不加区分，打击变革性与边际产品的研发动力。
我对其以价值为导向几乎没有信心。也就是说，我怀疑政府会削减边际商品和服务的支出并激励创新和有价值的服务。更可能的是做法草率且不加区分，导致变革性产品和边际产品都缺乏研发动力。原文 (en)
I have little confidence it will be value driven. In other words, I doubt that government will reduce spending on marginal goods and service and incentivize innovation and valuable services. Instead, very likely it will be done haphazardly and indiscriminately resulting in disincentives to make transformative products and marginal products alike.
Prasad 警告控费将依赖分层和任意延迟，使美国消费者获取新疗法时更加受挫。
同样，由于我们无法区分好产品和边际产品，成本控制将依赖分层结构、任意拖延等手段，这很可能进一步加剧美国消费者的不满。原文 (en)
Again, because we are unable to differentiate good vs marginal products, cost control will rely on tiered structures, arbitrary delays, etc. This will likely result in further frustration from the American consumer.
Prasad认为冒烟型骨髓瘤试验中唯一有意义的终点是总生存期，因为早期治疗在未证明获益时只会增加毒性和成本。
对于冒烟型骨髓瘤，唯一重要的终点是总生存期。毕竟，用权宜性方案治疗癌前状态，从定义上就增加了毒性和成本。肿瘤最终仍会生长，最终仍会致命。原文 (en)
With smoldering myeloma, the only endpoint that matters is overall survival. After all, if you treat a pre-cancer with a temporizing regimen, you add toxicity and cost, by definition. Your tumor will still eventually grow, and it will still eventually kill you.